Stifel analyst Justin Keywood raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$20 from C$17 and keeps a Buy rating on the shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPHRF:
- Cipher Pharmaceuticals price target raised to C$14 from C$13 at Canaccord
- Cipher Pharmaceuticals Reports Record Q2 2025 Revenue
- Cipher Pharmaceuticals Achieves Record Revenue in Q2 2025
- Cipher Pharmaceuticals to Announce Q2 2025 Financial Results
- Cipher Pharmaceuticals’ Shareholders Approve Key Resolutions at Annual Meeting